Biofrontera Inc., often referred to by its stock market acronym, BFRI, is a biotechnology company specializing in high-quality pharmaceutical research. The company is a subsidiary of Biofrontera AG, a German pharmaceutical company that operates at an international level. Biofrontera Inc., in its commitment to improving the lives of patients, primarily focuses on diagnosing and treating dermatological conditions and diseases, with a special emphasis on skin cancer.
Founded in 1997, Biofrontera AG has since expanded across the globe, bringing with it its dedicated subsidiary, Biofrontera Inc. The company is known for its breakthrough discoveries and significant contributions to the medical field, particularly in the area of dermatology. It has been recognized for its novel medicines designed to help patients with skin-related diseases lead healthier and more comfortable lives.
Biofrontera Inc.'s standout portfolio includes the widely recognized drug, Ameluz®. This medication, approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is used primarily for the treatment of actinic keratosis, a precancerous skin condition. The topical formulation coupled with photodynamic therapy (PDT) has shown pronounced effectiveness in patients with superficial and nodular basal cell carcinoma.
The company's second product, BF-RhodoLED®, is a lamp designed for PDT with Ameluz®. With its innovative technologies, the company has been able to take strides towards effective treatments that are less harmful to patients than traditional therapies. Besides its noteworthy products, Biofrontera is committed to progressing medical knowledge through ongoing research and development efforts, continually exploring more efficacious treatment methods for skin diseases.
Biofrontera Inc.'s operations are thriving under a proficient management team that includes a mix of experienced senior executives and emerging talent. Together, they aim to uphold Biofrontera Inc.'s reputation for healthcare innovation. Despite its global operations, the company remains deeply committed to scientific advancements that benefit patients, stakeholders, and the medical community worldwide.
In the stock market, BFRI has displayed potential growth, reflecting the company's robust research and development strategies, its innovative products, and its consistent focus on enhancing patient care. By diligently working towards improving the current skin cancer treatment landscape, Biofrontera Inc. enhances the quality of life for countless individuals while prioritizing scientific research and its commitment to accretive growth.